A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets
Latest Information Update: 06 Mar 2023
At a glance
- Drugs TQB 3473 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 29 Mar 2021 Status changed from not yet recruiting to recruiting.
- 05 Jun 2020 New trial record